Prakt. lékáren. 2014; 10(5): 180-185

Pharmaceutical care in cardiovascular prevention

Kateřina Ládová, Petra Matoulková
Katedra sociální a klinické farmacie, Farmaceutická fakulta v Hradci Králové, Univerzita Karlova v Praze

Cardiovascular (CV) prevention is one of the reasons of CV mortality and morbidity decrease, therefore it is necessary to pay maximum

attention to it. This paper introduce some aspects related to the involvement of pharmacists in CV prevention within dispensing

and counseling activities in the pharmacy. There is outlined how pharmacists can contribute to the identification of patients with CV

risk and consequently intervene appropriately, especially by rational non-pharmacological approaches. Minimization of risks associated

with use of drugs which can increase CV risk and barriers in providing of pharmaceutical care in CV prevention are also included.

Keywords: pharmaceutical care, cardiovascular risk, prevention, risk factors

Published: October 24, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ládová K, Matoulková P. Pharmaceutical care in cardiovascular prevention. Praktické lékárenství. 2014;10(5):180-185.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Býma S, Hradec J. Doporučený diagnostický a terapeutický postup pro všeobecné praktické lékaře. Prevence kardiovaskulárních onemocnění. Novelizace 2013. Praha: CDP-PL, 2013: 17.
    2. World Health Organization. Global Atlas on cardiovascular disease prevention and control. Geneva: WHO library Cataloguing-in-Publication Data, 2011: 155 p.
    3. Vlcek J, Maly J, Dosedel M. Pharmaceutical care of patients with diabetes mellitus and its relationship to clinical pharmacy. Vnitr Lek. 2009; 55: 384-388. Go to PubMed...
    4. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Amer J Hosp Pharm. 1990; 47(3): 533-543. Go to original source...
    5. Kolář J, Macešková B. Současné přístupy k farmakoterapii - farmaceutická péče nebo management léků? Ceska Slov Farm. 2010; 59(1): 7-10.
    6. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012; 19(4): 403-488. Go to original source... Go to PubMed...
    7. International Pharmaceutical Federation. 2013 FIPEd global education report. Hague: International Pharmaceutical Federation, 2013: 52 p.
    8. George J, McNamara K, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. Australas Med J. 2011; 4(5): 266-272. Go to original source... Go to PubMed...
    9. O'Loughlin J, Masson P, Déry V, et al. The role of community pharmacists in health education and disease prevention: a survey of their interests and needs in relation to cardiovascular disease. Prev Med. 1999; 28(3): 324-331. Go to original source... Go to PubMed...
    10. Schwappach DL, Boluarte TA, Suhrcke M. The economics of primary prevention of cardiovascular disease - a systematic review of economic evaluations. Cost Eff Resour Alloc. 2007; 5(5): 1-12. Go to original source... Go to PubMed...
    11. Jekel JF, Katz DL, Elmore JG, et al. Epidemiology, biostatistics, and preventive medicine. Third edition. Philadelphia: Elsevier Health Sciences, 2007: 448 p.
    12. Kones R, Rumana U. Prevention of cardiovascular disease: updating the immensity of the challenge and the role of risk factors. Hosp Pract (1995). 2014; 42(1): 92-100. Go to original source... Go to PubMed...
    13. Soška V, Vaverková H, Vráblík M, a kol. Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidelines related to the diagnostics and treatment of dyslipidemias issued in 2011. Vnitr Lek. 2013; 59(2): 120-126. Go to PubMed...
    14. Státní zdravotní ústav. Odhad kardiovaskulárního rizika metodou SCORE. [online]. [cit. 2014-07-31]. Dostupné z: <http://www.szu.cz/tema/prevence/score>.
    15. Mc Namara KP, Dunbar JA, Philpot B, et al. Potential of pharmacists to help reduce the burden of poorly managed cardiovascular risk. Aust J Rural Health. 2012; 20(2): 67-73. Go to original source... Go to PubMed...
    16. Dunbar A, Gotsis W, Frishman W. Second-hand tobacco smoke and cardiovascular disease risk: an epidemiological review. Cardiol Rev. 2013; 21(2): 94-100. Go to original source... Go to PubMed...
    17. Rigotti NA, Clair C. Managing tobacco use: the neglected cardiovascular disease risk factor. Eur Heart J. 2013; 34(42): 3259-3267. Go to original source... Go to PubMed...
    18. Ficnerová J, Petrášová P. Doporučený postup. Poradenství při odvykání kouření. Česká lékárnická komora. [online]. [cit. 2014-7-15]. Dostupné z: <http://www.lekarnici.cz/Pro-cleny/Doporucene-postupy/prilohy/DP - koureni.aspx>.
    19. Odborné poradenství v lékárnách. Česká lékárnická komora. [online]. [cit. 2014-7-15]. Dostupné z: <http://www.lekarnici.cz/Pro-verejnost/Odborne-poradenstvi-v-lekarnach.aspx>.
    20. Chaloupka V, Elbl L, Nehyba S, a kol. Pohybová aktivita u nemocných s kardiovaskulárním onemocněním. Kardiol Rev Int Med. 2003; (1): 16-19.
    21. Němcová H. Pohybová aktivita v prevenci civilizačních chorob. Doporučené postupy pro praktické lékaře. Praha: ČLS JEP, 2002: 12 s.
    22. Anonymous. Dieta v prevenci aterosklerózy. Farmakoterapeutické informace. Měsíčník pro lékaře a farmaceuty. SÚKL. 2013; 10: 1-3.
    23. Dalen JE, Devries S. Diets to Prevent Coronary Heart Disease 1957-2013: What Have We Learned? Am J Med. 2014; 127: 364-369. Go to original source... Go to PubMed...
    24. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013; 368: 1279-1290. Go to original source... Go to PubMed...
    25. Becker DJ, French B, Morris PB, et al. Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial. Am Heart J. 2013; 166(1): 187-196. Go to original source... Go to PubMed...
    26. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med. 2014; 160(6): 398-406. Go to original source... Go to PubMed...
    27. Bray G, Look M, Ryan D. Treatment of the obese patient in primary care: targeting and meeting goals and expectations. Postgrad Med. 2013; 125(5): 67-77. Go to original source... Go to PubMed...
    28. Dobrucká K, Malý J, Vlček J. Analýza role farmaceuta při poskytování konzultací pacientům s rizikem nadváhy nebo obezity v lékárně. Klin Farmakol Farm. 2012; 26(3): 117-120.
    29. Whalley B, Rees K, Davies P, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev. 2011; 10(8): in press. Go to original source... Go to PubMed...
    30. George PP, Molina JA, Cheah J, et al. The evolving role of the community pharmacist in chronic disease management - a literature review. Ann Acad Med Singapore. 2010; 39(11): 861-867. Go to original source...
    31. Alušík Š, a kol. Klinické projevy nežádoucích účinků léků. Praha: Triton, 2001: 170 s.
    32. Tisdale JE, Miller DA. Drug-induced Diseases: Prevention, Detection, and Management. Second edition. Bethesda: ASHP, 2010: 1110 p.
    33. Svačina Š. Vedlejší účinky farmakoterpie na hladinu lipidů. Vnitr Lek. 2007; 53(4): 408-411. Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.